Clear cell renal carcinoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:319276C64
Who is this for?
Show terms as
1FDA treatments100Active trials184Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Clear cell renal cell carcinoma (also called clear cell RCC, ccRCC, or conventional renal cell carcinoma) is the most common type of kidney cancer in adults. It starts in the lining of the tiny tubes inside the kidney that help filter blood and make urine. Under a microscope, the cancer cells look pale or 'clear,' which is how the disease gets its name. The cancer can grow slowly or quickly, and it may spread to other parts of the body such as the lungs, bones, liver, or brain if not caught early. Common symptoms include blood in the urine, a lump or pain in the side or lower back, unexplained weight loss, and persistent fatigue. Many people have no symptoms at all in the early stages, and the tumor is often found by accident during imaging done for another reason. Treatment depends on how advanced the cancer is. Surgery to remove part or all of the kidney is the main treatment for early-stage disease and can be curative. For advanced or metastatic disease, targeted therapies and immunotherapy drugs are the backbone of treatment. Several FDA-approved medicines are available, including sunitinib, pazopanib, cabozantinib, nivolumab, pembrolizumab, and combination regimens. Research is very active, and new treatments continue to improve outcomes for patients.

Also known as:

Key symptoms:

Blood in the urine (urine may look pink, red, or cola-colored)A lump or mass felt in the side, back, or abdomenPersistent pain in the side or lower backUnexplained weight lossExtreme tiredness or fatigueFever that keeps coming back without infectionLoss of appetiteSwelling in the legs or anklesHigh blood pressure that is hard to controlAnemia (low red blood cell count causing paleness and weakness)Bone pain (if cancer has spread to bones)Shortness of breath (if cancer has spread to lungs)

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Aug 2026Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment

Gruppo Oncologico Italiano di Ricerca Clinica — PHASE2

TrialNOT YET RECRUITING
Jun 2026Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

SWOG Cancer Research Network — PHASE3

TrialNOT YET RECRUITING
Jun 2026Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

City of Hope Medical Center — PHASE2

TrialNOT YET RECRUITING
May 2026UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma

UTC Therapeutics Inc. — PHASE1

TrialNOT YET RECRUITING
May 2026Lu-177 PSMA Treatment in Cell Renal Carcinoma

Ankara University — PHASE3

TrialNOT YET RECRUITING
Apr 2026Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

City of Hope Medical Center — PHASE1

TrialRECRUITING
Mar 2026Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

M.D. Anderson Cancer Center — PHASE1

TrialNOT YET RECRUITING
Mar 2026CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC

Massachusetts General Hospital — PHASE2

TrialNOT YET RECRUITING
Mar 2026Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Karie Runcie — PHASE2

TrialRECRUITING
Mar 2026Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Dana-Farber Cancer Institute — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Torisel

Temsirolimus· Wyeth Pharmaceuticals, Inc.Orphan Drug

Treatment of advanced renal cell carcinoma

Clinical Trials

20 recruitingView all trials with filters →
Phase 38 trials
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Phase 3
Actively Recruiting
PI: Pamela Munster, M.D. (University of California, San Francisco) · Sites: Phoenix, Arizona; Sacramento, California +36 more · Age: 1899 yrs
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Phase 3
Active
PI: Medical Director (Merck Sharp & Dohme LLC) · Sites: Birmingham, Alabama; La Jolla, California +260 more · Age: 1899 yrs
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Phase 3
Actively Recruiting
· Sites: Phoenix, Arizona; Tucson, Arizona +397 more · Age: 1899 yrs
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Phase 3
Active
· Sites: Duarte, California; Newport Beach, California +161 more · Age: 1899 yrs
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
Phase 3
Active
PI: Marine GROSS-GOUPIL, MD PhD (University Hospital, Bordeaux) · Sites: Bayonne; Bordeaux +24 more · Age: 1899 yrs
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
Phase 3
Active
· Sites: La Jolla, California; Aurora, Colorado +30 more · Age: 1899 yrs
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
Phase 3
Active
PI: Tian Zhang (Alliance for Clinical Trials in Oncology) · Sites: Mobile, Alabama; Anchorage, Alaska +860 more · Age: 1899 yrs
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Phase 3
Active
· Sites: Stanford, California; Boca Raton, Florida +181 more · Age: 1899 yrs
Other12 trials
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Actively Recruiting
PI: Dev Mukhopadhyay, PhD (Mayo Clinic) · Sites: Phoenix, Arizona; Jacksonville, Florida +1 more · Age: 1899 yrs
Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer
Actively Recruiting
· Sites: Milan, MI · Age: 1899 yrs
Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning
Active
· Sites: Fuzhou, Fujian
Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma
Actively Recruiting
PI: Li Zhang, Dr. (The First Affiliated Hospital of Shandong First Me) · Sites: Jinan
Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell Carcinoma
Actively Recruiting
PI: Hiroshi Onishi, MD, PhD (University of Yamanashi) · Sites: Chūō, Yamanashi · Age: 1899 yrs
Dual-energy SPEctral CT to Evaluate Response to First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer
Actively Recruiting
PI: Francesco Massari, MD (IRCCS Azienda Ospedaliero-Universitaria di Bologna) · Sites: Bologna, BO; Bologna · Age: 1899 yrs
Multiomics Approach in Metastatic Clear Renal Cell Carcnoma
Active
PI: Giuseppe Procopio, MD (Fondazione IRCCS istituto Nazionale dei Tumori di ) · Sites: Milan, Mi · Age: 1899 yrs
Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer
Actively Recruiting
PI: Brigitta R Villumsen, PhD (Gødstrup Hospital) · Sites: Aalborg; Aarhus +1 more
Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma
Actively Recruiting
· Sites: Roskilde
Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma
Actively Recruiting
PI: Nicolas MOTTET, MD PhD (CHU SAINT-ETIENNE) · Sites: Saint-Etienne · Age: 1899 yrs
Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer
Active
PI: Bristol-Myers Squibb (Bristol-Myers Squibb) · Sites: Paris · Age: 1899 yrs
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Actively Recruiting
PI: Yuxiu Liu, M. D. (Jinling Hospital, China) · Sites: Nanjing, Jiangsu · Age: 1880 yrs

Specialists

Showing 25 of 184View all specialists →
SP
Sumanta K Pal
DUARTE, CA
Specialist
PI on 6 active trials25 Clear cell renal carcinoma publications
PM
Pavlos Msaouel
HOUSTON, TX
Specialist
PI on 2 active trials2 Clear cell renal carcinoma publications
GM
Giuseppe Procopio, MD
RAHWAY, NJ
Specialist
PI on 8 active trials1 Clear cell renal carcinoma publication
NM
Nizar M. Tannir, MD
HOUSTON, TX
Specialist
PI on 3 active trials
WM
Wenxin Xu, MD
BOSTON, MA
Specialist
PI on 2 active trials1 Clear cell renal carcinoma publication
AA
Andrea B Apolo
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 4 active trials
TM
Timothy M. Kuzel, MD
HOUSTON, TX
Specialist
PI on 11 active trials
DM
Darren Feldman, MD
NEW YORK, NY
Specialist
PI on 8 active trials
AF
André Poisl Fay
Specialist
PI on 2 active trials9 Clear cell renal carcinoma publications
WM
W. Marston Linehan, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 6 active trials
WM
Willis Navarro, MD
TUCSON, AZ
Specialist
PI on 4 active trials
KP
Kan Gong, PhD
NEW YORK, NY
Specialist
PI on 1 active trial
KG
Kan Gong
NEW YORK, NY
Specialist
PI on 3 active trials9 Clear cell renal carcinoma publications
TD
Thomas E. Olencki, DO
COLUMBUS, OH
Specialist
PI on 2 active trials
CM
Christopher W. Ryan, MD
Specialist
PI on 3 active trials
CR
Christopher Ryan
Specialist
PI on 3 active trials30 Clear cell renal carcinoma publications
EJ
Eric Jonasch
HOUSTON, TX
Specialist
PI on 3 active trials2 Clear cell renal carcinoma publications
AA
Ana Aparicio
GRANDVIEW, WA
Specialist
PI on 2 active trials2 Clear cell renal carcinoma publications
GM
Gnanamba V. Kondagunta, MD
MIDDLETOWN, NY
Specialist
PI on 3 active trials
MM
Melissa Huynh, MD
Specialist
PI on 2 active trials

Treatment Centers

8 centers
⚗️ Trial Site

CHI Saint Vincent Cancer Center Hot Springs

📍 Hot Springs, Arkansas

⚗️ Trial Site

Alta Bates Summit Medical Center-Herrick Campus

📍 Berkeley, California

⚗️ Trial Site

Sutter Auburn Faith Hospital

📍 Auburn, California

⚗️ Trial Site

Sutter Cancer Centers Radiation Oncology Services-Auburn

📍 Auburn, California

⚗️ Trial Site

Mills-Peninsula Medical Center

📍 Burlingame, California

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

Financial Resources

1 resources
Torisel(Temsirolimus)Wyeth Pharmaceuticals, Inc.

Travel Grants

No travel grants are currently matched to Clear cell renal carcinoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Clear cell renal carcinomaForum →

No community posts yet. Be the first to share your experience with Clear cell renal carcinoma.

Start the conversation →

Latest news about Clear cell renal carcinoma

Disease timeline:

New recruiting trial: Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell Carcinoma

A new clinical trial is recruiting patients for Clear cell renal carcinoma

New recruiting trial: Zero Ischemia Robot-Assisted MWA Assisted Suture-less Tumor Enucleation of RCC With T1 Stage

A new clinical trial is recruiting patients for Clear cell renal carcinoma

New recruiting trial: Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

A new clinical trial is recruiting patients for Clear cell renal carcinoma

New recruiting trial: Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma

A new clinical trial is recruiting patients for Clear cell renal carcinoma

New recruiting trial: The Efficacy and Safety of Liangxue Ointment in the Treatment of Hand-foot Syndrome Caused by VEGFR-TKI Drugs

A new clinical trial is recruiting patients for Clear cell renal carcinoma

New recruiting trial: Planning Operative Strategy Using a Digital Renal Artery Clamping Tool

A new clinical trial is recruiting patients for Clear cell renal carcinoma

New recruiting trial: A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

A new clinical trial is recruiting patients for Clear cell renal carcinoma

New recruiting trial: Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer

A new clinical trial is recruiting patients for Clear cell renal carcinoma

New recruiting trial: Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

A new clinical trial is recruiting patients for Clear cell renal carcinoma

New recruiting trial: Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

A new clinical trial is recruiting patients for Clear cell renal carcinoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What stage is my cancer, and what does that mean for my treatment options?,Should I have genetic testing to see if I have a hereditary syndrome like VHL disease?,Is surgery an option for me, and would I need to lose the whole kidney or just part of it?,What are the recommended first-line treatments for my stage, and what side effects should I expect?,Are there clinical trials I might be eligible for?,How often will I need imaging and blood tests to monitor for recurrence or progression?,What signs or symptoms should prompt me to call your office or go to the emergency room right away?

Common questions about Clear cell renal carcinoma

What is Clear cell renal carcinoma?

Clear cell renal cell carcinoma (also called clear cell RCC, ccRCC, or conventional renal cell carcinoma) is the most common type of kidney cancer in adults. It starts in the lining of the tiny tubes inside the kidney that help filter blood and make urine. Under a microscope, the cancer cells look pale or 'clear,' which is how the disease gets its name. The cancer can grow slowly or quickly, and it may spread to other parts of the body such as the lungs, bones, liver, or brain if not caught early. Common symptoms include blood in the urine, a lump or pain in the side or lower back, unexplaine

At what age does Clear cell renal carcinoma typically begin?

Typical onset of Clear cell renal carcinoma is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Clear cell renal carcinoma?

Yes — 20 recruiting clinical trials are currently listed for Clear cell renal carcinoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Clear cell renal carcinoma?

25 specialists and care centers treating Clear cell renal carcinoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.